(Q33282375)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17447423%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17447423%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

1

Daniela Berg

2 references

25 July 2017

ORCID Public Data File 2021

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17447423%20AND%20SRC:MED&resulttype=core&format=json

Journal of neural transmission. Supplementum

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17447423%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17447423%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

123-132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17447423%20AND%20SRC:MED&resulttype=core&format=json

Olfactory function in patients with Parkinson's disease

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Electrophysiological correlates of visual categorization: evidence for cognitive dysfunctions in early Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Parkinson's disease changes the balance of onset and offset visual responses: an evoked potential study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Experimental models of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Disturbance of sequential movements in patients with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Vulnerability of the nigrostriatal system as detected by transcranial ultrasound

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Growth hormone therapy in the glucocorticosteroid-dependent child: metabolic and linear growth effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Scavestrogens protect IMR 32 cells from oxidative stress-induced cell death.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Visual dysfunction in Parkinson's disease. Loss in spatiotemporal contrast sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Staging of brain pathology related to sporadic Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

The early diagnosis of Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Internal versus external cues and the control of attention in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Cognitive function in Parkinson's disease: From description to theory

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Parkinson's disease in twins studied with 18F-dopa and positron emission tomography

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Distorted color discrimination in 'de novo' parkinsonian patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

L-Dopa improves colour vision in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Alterations in chromatic contour perception in de novo parkinsonian patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Depression and Parkinson's disease: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Aminergic systems in Alzheimer's disease and Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Olfactory dysfunction in parkinsonism: A general deficit unrelated to neurologic signs, disease stage, or disease duration

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Cognitive deficits in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's d

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Familial aggregation of Parkinson's disease: A population-based case-control study in Europe

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Ageing and Parkinson's disease: substantia nigra regional selectivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Autonomic dysfunction in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F] dopa PET.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Olfactory dysfunction in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Different behaviors during paradoxical sleep without atonia depend on pontine lesion site.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Visuomotor control abnormalities in patients with unilateral parkinsonism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Depression in Parkinson's disease. The impact of symptom overlap on prevalence

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Clinical characteristics in early Parkinson's disease in a central California population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Cognitive deficits in the early stages of Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

When did Ray Kennedy's Parkinson's disease begin?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Association between early-onset Parkinson's disease and mutations in the parkin gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Detection of preclinical Parkinson disease in at-risk family members with use of [123I]beta-CIT and SPECT: an exploratory study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Risk of Parkinson's disease among first-degree relatives: A community-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Olfactory dysfunction in familial parkinsonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Depression, intellectual impairment, and Parkinson disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Psychiatric symptoms in Parkinsonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Abnormal performance on the PD test battery by asymptomatic first-degree relatives.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Early detection of probable idiopathic Parkinson's disease: I. Development of a diagnostic test battery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Early detection of probable idiopathic Parkinson's disease: II. A prospective application of a diagnostic test battery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Clinical and [18F] dopa PET findings in early Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Planning and spatial working memory in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

3-OMD and homocysteine plasma levels in parkinsonian patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Brain 6-[18F]fluorodopa metabolism in early and late onset of Parkinson's disease studied by positron emission tomography.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Increased risk of Parkinson's disease in parents and siblings of patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Dopaminergic function in familial Parkinson's disease: A clinical and18F-dopa positron emission tomography study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Idiopathic hyposmia as a preclinical sign of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Abnormalities in color vision and contrast sensitivity in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Olfactory threshold in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Depression in Patients with Parkinsonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Sleep patterning and behaviour in cats with pontine lesions creating REM without atonia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

REM sleep without atonia after lesions of the medial medulla.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

The Association of Ventral Tegmental Area Histopathology With Adult Dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

The pathology of REM sleep behavior disorder with comorbid Lewy body dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Incidental Lewy body disease in a patient with REM sleep behavior disorder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Brain parenchyma sonography detects preclinical parkinsonism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

The transition from adolescence to adult life: physiology of the 'transition' phase and its evolutionary basis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Olfactory impairment in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

Olfactory Deficits in Elderly Subjects and Parkinson Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-211-33328-0_14

10.1007/978-3-211-33328-0_14

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17447423%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference